BillionToOne Swings to Profit on Near-Doubled Revenue

Ticker: BLLN · Form: 10-Q · Filed: Dec 10, 2025 · CIK: 2070849

Sentiment: bullish

Topics: Precision Diagnostics, Prenatal Screening, Oncology, Revenue Growth, Profitability, Biotechnology, Medical Devices

TL;DR

**BLLN is finally turning a profit with massive revenue growth, making it a strong buy for long-term growth in precision diagnostics.**

AI Summary

BillionToOne, Inc. (BLLN) reported a significant increase in revenue and a return to net income for the nine months ended September 30, 2025. Revenue surged to $209.059 million, a substantial increase from $107.505 million in the same period of 2024, representing a 94.47% growth. The company achieved a net income of $1.477 million for the nine months ended September 30, 2025, a stark improvement from a net loss of $30.093 million in the prior year. Gross profit more than doubled to $139.854 million from $55.196 million year-over-year. Operating expenses increased to $134.163 million from $90.650 million, driven by higher research and development ($35.134 million vs. $25.600 million) and selling, general and administrative costs ($99.029 million vs. $65.050 million). Cash and cash equivalents increased to $195.152 million as of September 30, 2025, from $191.477 million at December 31, 2024. The company's accumulated deficit improved to $(280.724) million from $(282.201) million, reflecting the recent profitability. Key risks include the ability to advance product candidates through development and commercialization, and the expense of meeting regulatory requirements for new products.

Why It Matters

BillionToOne's impressive revenue growth and shift to profitability are critical for investors, signaling strong market adoption of its precision diagnostics in prenatal and oncology. This financial turnaround could attract more institutional investment, potentially driving up BLLN's stock price and improving its competitive standing against larger diagnostic firms. For employees, sustained profitability offers greater job security and potential for growth, while customers benefit from continued innovation in molecular diagnostics. The broader market gains a new, financially healthier player in the rapidly expanding precision medicine sector, intensifying competition and potentially accelerating advancements in disease detection.

Risk Assessment

Risk Level: medium — While BillionToOne achieved net income of $1.477 million for the nine months ended September 30, 2025, and significantly increased revenue, the company still carries an accumulated deficit of $(280.724) million. Furthermore, the filing explicitly states, "Certain of the Company's product candidates are in development. If the Company is unable to advance its product candidates through development, clinical validation and ultimately commercialize its product candidates, or experiences significant delays in doing so, the Company's business will be materially harmed." This reliance on future product commercialization, coupled with the historical accumulated deficit, indicates a medium risk profile.

Analyst Insight

Investors should consider initiating a position in BLLN, given the strong revenue growth of 94.47% and the significant swing to net income of $1.477 million. Monitor the company's progress in commercializing new product candidates and its ability to manage operating expenses, as these will be crucial for sustained profitability and long-term value creation.

Financial Highlights

revenue
$209.059M
operating Margin
2.72%
total Assets
$327.521M
total Debt
$55.446M
net Income
$1.477M
eps
$0.03
gross Margin
66.90%
cash Position
$195.152M
revenue Growth
+94.47%

Key Numbers

Key Players & Entities

FAQ

What were BillionToOne's key financial results for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, BillionToOne reported revenue of $209.059 million, a significant increase from $107.505 million in the prior year. The company also achieved a net income of $1.477 million, a substantial improvement from a net loss of $30.093 million in the same period of 2024.

How did BillionToOne's operating expenses change year-over-year?

BillionToOne's total operating expenses increased to $134.163 million for the nine months ended September 30, 2025, up from $90.650 million in the prior year. This rise was primarily driven by increases in research and development expenses to $35.134 million and selling, general and administrative expenses to $99.029 million.

What is BillionToOne's current cash position?

As of September 30, 2025, BillionToOne had cash and cash equivalents totaling $195.152 million. This represents an increase from $191.477 million reported at December 31, 2024.

What are the primary business areas for BillionToOne, Inc.?

BillionToOne, Inc. applies its proprietary molecular counting platform to non-invasive prenatal screening ("Prenatal") and liquid biopsy ("Oncology"). The company's technology is designed to detect and measure DNA molecules at the single-count level to improve disease detection.

What is the significance of BillionToOne's shift to net income?

The shift to a net income of $1.477 million for the nine months ended September 30, 2025, from a net loss of $30.093 million in the prior year, indicates a significant improvement in BillionToOne's financial performance and operational efficiency. This positive change suggests growing market acceptance of its products and better cost management.

What are the key risks identified in BillionToOne's 10-Q filing?

A key risk highlighted in BillionToOne's 10-Q filing is the company's ability to advance its product candidates through development, clinical validation, and commercialization. Delays or failures in this process could materially harm the business, and meeting regulatory requirements for new products is an expensive endeavor.

How has BillionToOne's accumulated deficit changed?

BillionToOne's accumulated deficit improved to $(280.724) million as of September 30, 2025, from $(282.201) million at December 31, 2024. This reduction reflects the company's recent net income contributing to a decrease in its historical losses.

What is BillionToOne's stock structure as of December 5, 2025?

As of December 5, 2025, BillionToOne had 41,216,110 shares of Class A common stock, par value $0.00001 per share, and 4,552,650 shares of Class B common stock, par value $0.00001 per share outstanding.

What is BillionToOne's status regarding being an emerging growth company?

BillionToOne is an emerging growth company, as indicated by the checkmark in the 10-Q filing. This status provides certain exemptions from new or revised financial accounting standards.

What was the change in fair value of BillionToOne's term loan for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, BillionToOne reported a change in fair value of the term loan of $(7.038) million, compared to $(2.283) million in the same period of 2024.

Risk Factors

Industry Context

BillionToOne, Inc. operates in the biotechnology or healthcare sector, likely focused on diagnostics or therapeutics. This industry is characterized by high R&D investment, long development cycles, and significant regulatory oversight from bodies like the FDA. Success hinges on innovation, clinical trial outcomes, and effective commercialization strategies in a competitive landscape with both established players and emerging startups.

Regulatory Implications

The company's product development pipeline is subject to rigorous regulatory review. Successful navigation of these processes is critical for market access and revenue generation. Any delays or failures in regulatory approval could severely impact financial performance and future prospects.

What Investors Should Do

  1. Monitor R&D and SG&A expense growth relative to revenue.
  2. Analyze gross margin trends.
  3. Evaluate the company's ability to manage its substantial redeemable convertible preferred stock.
  4. Assess progress on product development and regulatory milestones.

Key Dates

Glossary

Accumulated deficit
The total net losses of a company since its inception, minus any net gains. It represents the cumulative loss that has not been offset by profits. (An improvement in the accumulated deficit, as seen by BillionToOne, Inc., indicates the company is moving towards profitability and reducing its historical losses.)
Redeemable convertible preferred stock
A class of stock that has features of both preferred stock (fixed dividend, liquidation preference) and common stock (convertibility), with an added provision that allows holders to redeem their shares for cash under certain conditions. (This represents a significant liability on the balance sheet ($419.409M) and can impact future equity structure and cash flows upon redemption.)
Operating lease right-of-use assets, net
An asset recognized under accounting standards (ASC 842) representing a lessee's right to use an underlying asset for the lease term. (The company has substantial operating lease liabilities ($47.046M non-current, $4.902M current), indicating significant fixed asset commitments related to leases.)
Cost of revenue
The direct costs attributable to the production or purchase of the goods or services sold by a company. (Understanding the trend in cost of revenue relative to revenue is crucial for assessing gross profit margins and operational efficiency.)

Year-Over-Year Comparison

BillionToOne, Inc. has demonstrated a dramatic turnaround in performance compared to the prior year. Revenue for the nine months ended September 30, 2025, more than doubled to $209.059 million from $107.505 million in 2024, a 94.47% increase. This top-line growth, coupled with improved cost management relative to revenue, allowed the company to swing from a net loss of $30.093 million to a net income of $1.477 million. Gross profit margins have also significantly expanded. While operating expenses have risen, they have done so at a slower pace than revenue, leading to improved profitability and a reduction in the accumulated deficit.

Filing Stats: 4,551 words · 18 min read · ~15 pages · Grade level 20 · Accepted 2025-12-10 16:30:15

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION 4 ITEM 1.

FINANCIAL STATEMENTS (UNAUDITED)

FINANCIAL STATEMENTS (UNAUDITED) 4 Balance Sheets 4 5 6 8 Notes to Unaudited Interim Financial Statements 10 ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 28 ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 46 ITEM 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 47

OTHER INFORMATION

PART II OTHER INFORMATION 49 ITEM 1.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 49 ITEM 1A.

RISK FACTORS

RISK FACTORS 49 ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 94 ITEM 3. DEFAULTS UPON SENIOR SECURITIES 95 ITEM 4. MINE SAFETY DISCLOSURES 95 ITEM 5. OTHER INFORMATION 95 ITEM 6. EXHIBITS 95

SIGNATURES

SIGNATURES 97 1 Table of Contents Special Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q (this "Quarterly Report") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future operating results and financial position, our business strategy and plans, our market growth, and our objectives for future operations, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "forecast," "could," "plan," "potential," "predict," "seek," "target," "should," "would," or the negative version of these words and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs. Forward-looking statements contained in this Quarterly Report include, but are not limited to, statements about: the level of demand for any of our products, which may vary significantly; our ability to increase the adoption of our products in the prenatal and oncology markets and in large healthcare systems; our ability to generate persuasive clinical validity and utility evidence; our ability to expand our portfolio of molecular diagnostic tests; our ability to use AI effectively and efficiently; our ability to execute our reimbursement strategy and expand coverage of our tests; our ability to replicate positive results from trials or studies conducted by us or third parties in current or future trials or studies; the potential for our UNITY Fetal Antigen CTA to become the first

- Financial Information

Part I - Financial Information

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) BillionToOne, Inc Balance Sheets (in thousands, except share amounts, unaudited) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 195,152 $ 191,477 Accounts receivable 34,646 24,709 Inventories 17,389 8,733 Prepaid expenses and other current assets 4,529 2,898 Total current assets 251,716 227,817 Property and equipment, net 18,667 17,111 Operating lease right-of-use assets, net 48,024 51,739 Other non-current assets 9,114 5,392 Total assets $ 327,521 $ 302,059 Liabilities, redeemable convertible preferred stock, and stockholders' deficit Current liabilities: Accounts payable $ 7,806 $ 4,304 Accrued expenses and other current liabilities 8,041 3,882 Accrued commissions 2,922 2,756 Accrued compensation and employee benefits 13,687 8,419 Deferred revenue, current 2,683 2,806 Operating lease liabilities, current 4,902 4,393 Financing lease liabilities, current 744 1,826 Total current liabilities 40,785 28,386 Operating lease liabilities, non-current 47,046 50,802 Financing lease liabilities, non-current 460 874 Long-term debt 54,986 51,481 Other non-current liabilities 4,348 2,763 Total liabilities 147,625 134,306 Commitments and contingencies (Note 7) Redeemable convertible preferred stock, $ 0.00001 par value; 29,544,989 shares authorized as of September 30, 2025 and December 31, 2024; 29,084,235 shares issued and outstanding as of September 30, 2025 and December 31, 2024; aggregate liquidation preference of $ 422,458 as of September 30, 2025 and December 31, 2024 419,409 419,409 Stockholders' deficit: Common stock, $ 0.00001 par value, 51,100,000 shares authorized as of September 30, 2025 and December 31, 2024; 11,178,467 and 10,925,950 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively - - Additional paid-in capital 41,211 30,545 Accumulated deficit ( 280,724 ) ( 282,201 ) Total stockholders' deficit ( 239,

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing